Suppr超能文献

氢吗啡酮:不断发展以应对当今医疗保健环境的挑战。

Hydromorphone: evolving to meet the challenges of today's health care environment.

机构信息

Department of Pharmacy, Truman Medical Centers-Hospital Hill, Kansas City, Missouri.

出版信息

Clin Ther. 2013 Dec;35(12):2007-27. doi: 10.1016/j.clinthera.2013.09.027. Epub 2013 Nov 28.

Abstract

BACKGROUND

Hydromorphone, a potent analogue of morphine, has long had an important role in pain management and is included in several international guidelines for managing pain. Advances in hydromorphone formulations and the ways in which hydromorphone is being used clinically today warrant a review of the drug's pharmacotherapeutic utility.

OBJECTIVE

The history and recent advances in hydromorphone pharmacotherapy are reviewed. Areas covered include the pharmacologic and metabolic profile of hydromorphone, the role of hydromorphone in pain management, formulations and routes of administration, and issues related to relative opioid potencies, equianalgesic ratios, and opioid rotation. Because hydromorphone, like all opioids, carries a risk of misuse, abuse, and illicit diversion, the related issues of tamper-resistant formulations and "dose-dumping" of extended-release formulations are discussed.

CONCLUSIONS

Due to the epidemic of prescription opioid overdoses associated with prescription opioid abuse in the United States, development of tamper-resistant opioid formulations that avoid dose-dumping issues has become a significant goal of pharmaceutical manufacturers. The current formulation of hydromorphone extended-release potentially provides the benefits of long-acting hydromorphone (ie, continuous pain control, increased quality of life, freedom to perform daily activities) to appropriate patients, while reducing the risks of abuse and without compromising safety.

摘要

背景

氢吗啡酮是一种强效吗啡类似物,在疼痛管理中一直具有重要作用,并且被纳入了几种管理疼痛的国际指南中。氢吗啡酮制剂的进步以及当前临床应用氢吗啡酮的方式使得有必要重新评估该药物的治疗效用。

目的

本文回顾了氢吗啡酮的药理学治疗进展。涵盖的内容包括氢吗啡酮的药理学和代谢特征、在疼痛管理中的作用、制剂和给药途径,以及与相对阿片类药物效力、等效镇痛比和阿片类药物转换相关的问题。由于氢吗啡酮与所有阿片类药物一样存在误用、滥用和非法转移的风险,因此还讨论了具有抗篡改特性的制剂和控释制剂“剂量倾泻”相关的问题。

结论

由于与美国处方类阿片药物滥用相关的处方类阿片药物过量流行,开发避免剂量倾泻问题的抗篡改类阿片药物制剂已成为制药商的重要目标。氢吗啡酮控释制剂目前的剂型为合适的患者提供了长效氢吗啡酮(即持续疼痛控制、提高生活质量、可自由进行日常活动)的益处,同时降低了滥用风险,且不影响安全性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验